TENEOTWO
TeneoTwo is a biotechnology firm that develops potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Integral Molecular
Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies
MabSpace Biosciences
MabSpace Biosciences is a biotech company focused on discovery & development of innovative antibody based therapeutics for cancer.
MSI Methylation Sciences
MSI Methylation Sciences is a biotechnology company that develops and markets S-Adenosyl Methionine.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
More informations about "TeneoTwo"
Acquisition of TeneoTwo for its clinical-stage T-cell ... - AstraZeneca
Aug 11, 2022 AstraZeneca has completed the acquisition of TeneoTwo, Inc. (TeneoTwo) i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under …See details»
TeneoTwo, put in play by Amgen, lands $100M …
Jul 5, 2022 AstraZeneca has snapped up TeneoTwo and its drug candidate for $100 million upfront, plus up to $805 million in R&D-related milestones. If TNB-486 then makes it to market, TeneoTwo’s owners ...See details»
AstraZeneca to acquire TeneoTwo and its clinical-stage …
Jul 5, 2022 AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo) i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non …See details»
Acquisition of TeneoTwo for its clinical-stage T-cell engager …
Aug 11, 2022 AstraZeneca has completed the acquisition of TeneoTwo, Inc. (TeneoTwo) i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under …See details»
TeneoTwo Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore TeneoTwo Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 4 news.See details»
AstraZeneca to buy biotech firm TeneoTwo for up to $1.27 billion
Jul 5, 2022 TeneoTwo's experimental drug, TNB-486, belongs to a class of bispecific antibodies that are engineered to redirect the immune system to recognise and kill cancer cells. At the …See details»
TeneoTwo - Crunchbase
TeneoTwo is a biotechnology firm that develops potential new medicine for B-cell haematologic malignancies.See details»
TeneoTwo - Updates, News, Events, Signals & Triggers - Crunchbase
Jul 5, 2022 TeneoTwo is a biotechnology firm that develops potential new medicine for B-cell haematologic malignancies.See details»
AstraZeneca to buy oncology firm TeneoTwo for up to $1.27 bln
July 5 (Reuters) - AstraZeneca AZN.L said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager. The ...See details»
UPDATE 2-AstraZeneca to buy biotech firm TeneoTwo for up to …
Jul 5, 2022 AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers. …See details»
Ancora Biotech: TeneoTwo Acquisition & What’s Next
Jul 7, 2022 Original Article By Galym Imanbayev and Jonathan MacQuitty – on Medium. Today, AstraZeneca announced its agreement to acquire TeneoTwo, a subsidiary of TBio which is …See details»
Ancora Biotech: TeneoTwo Acquisition & What’s Next
Jul 5, 2022 By Galym Imanbayev and Jonathan MacQuitty. Today, AstraZeneca announced its agreement to acquire TeneoTwo, a subsidiary of TBio which is managed by Ancora Biotech, …See details»
AstraZeneca signs agreement to acquire TeneoTwo
Jul 5, 2022 Furthermore, equity holders of TeneoTwo are entitled to get up to $805m in research and development (R&D)-based milestone payments as well as up to $360m as commercial …See details»
AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo
Jul 5, 2022 AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers. The big pharma is …See details»
AstraZeneca broadens its scope in blood cancers with $100M …
Jul 5, 2022 The pharmaceutical giant announced Tuesday that it has agreed to pay $100 million up front to acquire TeneoTwo. Phase 1 testing of the biotech’s drug, TNB-486, is underway in …See details»
TeneoTwo, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore TeneoTwo, Inc. with its drug pipeline, therapeutic area, technology platform, 4 news.See details»
TeneoTwo Company Profile 2024: Valuation, Investors ... - PitchBook
TeneoTwo is a Private company. What is the current valuation of TeneoTwo? The current valuation of TeneoTwo is . What is TeneoTwo’s current revenue? The current revenue for …See details»
Ancora Biotech: TeneoTwo Acquisition & What’s Next - Medium
Jul 5, 2022 Today, AstraZeneca announced its agreement to acquire TeneoTwo, a subsidiary of TBio which is managed by Ancora Biotech, for $100M upfront as part of a total transaction …See details»
AstraZeneca completes acquisition of TeneoTwo - NLS
Aug 12, 2022 The pharma giant has completed the acquisition of TeneoTwo (announced July 5 2022), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under …See details»